Engineered t cells take on Hard-to-Treat blood cancers
NCT ID NCT00466531
First seen Apr 19, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This study tests a treatment for people with certain types of leukemia or lymphoma that have come back or not responded to standard chemotherapy. The approach takes a patient's own immune cells (T cells), modifies them in the lab to target a protein called CD19 found on cancer cells, and then returns them to the patient. The goal is to control the cancer, but ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.